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Current guidelines
Numerous organizations have provided guidelines for clinical
follow-up of women after they have undergone breast cancer
treatment. The American Society of Clinical Oncology
(ASCO) recommends clinic visits every 3 to 6 months for the
first 3 years, visits every 6 to 12 months for the next 2 years,
and annual visits after 5 years, with no advice on discharging
patients [1]. The Canadian Steering Committee on Clinical
Practice Guidelines for the Care and Treatment of Breast
Cancer are more pragmatic regarding the frequency of visits,
and suggests that these should be tailored to individual
patient needs, but their recommendations explicitly state that
follow-up should be provided indefinitely [2]. The National
Institute for Health and Clinical Excellence (NICE) in the UK
suggests that clinical follow-up should be limited to only 2 or
3 years [3].
There is also varying advice regarding mammographic follow-
up. Mammography is recognized as important in the
Canadian guidelines, with mammograms recommended
annually [2], although the Canadian guidelines do concede
that there is little high level evidence to support this practice.
Similar recommendations are made by ASCO [1]. In contrast,
NICE suggests that the yield of mammography is low and that
local networks should decide on their own policy. The British
Association of Surgical Oncology has reported that the ideal
frequency of mammography has not yet been established and
that mammography every 1 to 2 years should be undertaken
for up to 10 years after diagnosis [4]. There is clearly dis-
agreement between the groups that have published guide-
lines, but common to all of the guidelines is an emphasis on
providing intensive follow-up during the first 3 to 5 years after
diagnosis and treatment, with either reduced frequency of
visits or discharge to the general practitioner thereafter. The
bases of these guidelines are the perceptions that recurrent
disease is most common in the first 3 to 5 years after
treatment and that clinical examination remains an important
component of follow-up.
Aims of follow-up
NICE has defined the aims and objectives of follow-up: to
detect and treat local recurrence; to deal with adverse effects
of treatment; and to provide psychological support. Routine
surveillance of metastatic disease is not recommended
because data from two randomized studies revealed no
improvement in outcomes for patients who undergo intensive
programmes to detect and treat metastatic disease.
The GIVIO (Italian Interdisciplinary Group for Cancer Care
Evaluation) investigators randomized a series of 1,320
patients with stage I, II and III unilateral primary breast cancer
[5]. Patients were randomly assigned either to an intensive
follow-up programme of regular bone scans, liver ultrasound,
chest radiography and biochemical profile, or to a control
group receiving standard care. The control group underwent
regular clinical examinations and further tests as clinically
indicated. Both groups had annual mammography. At a
follow-up of 71 months, metastatic disease was detected in
31% of patients in the intensively observed group and in only
21% of patients in the group screened by clinical examination
and mammography alone. In those in whom metastatic
disease was detected, there was no significant difference in
the mean time to detection of this disease (53.39 months in
the intensive group versus 54.07 months in the standard care
group). There was also no difference between the two groups
in overall 5-year survival. The study identified no differences
between the two groups in overall health, quality of life,
emotional well being, body image, social functioning and satis-
faction with care at 6, 12, 24 and 60 months of follow-up.
The second trial, that conducted by Del Turco and colleagues
[6], randomly assigned 1,234 patients with invasive unilateral
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cancers but no distant metastasis to an intensive follow-up
programme of chest radiography and bone scans every
6 months, or to standard clinical follow-up. Although there
were significantly more isolated intrathoracic and bone
metastases detected in the intensively studied group, there
was again no difference in survival. One potential criticism of
both of these trials was that the duration of follow-up was
short, only 5 years at the time of publication. Subsequent
publication of 10-year follow-up data from the latter study,
which revealed identical survival rates between those under-
going intensive follow-up and those having clinical examina-
tion and mammography alone, addressed this criticism [7].
Intensive follow-up protocols require more clinical time, are
more costly and are responsible for diagnosing relatively few
asymptomatic relapses. There were a large number of false-
positive scans and unnecessary investigations in the patients
included in the intensively monitored group in both ran-
domized studies, increasing anxiety in a significant number of
patients [5-7].
The conclusion from these two randomized studies was that
intensive follow-up programmes should be abandoned. None
of the guidelines currently recommend such intensive follow-
up. The randomized studies did use old technological investi-
gations and were conducted at a time when therapy was
limited. More effective systemic therapies are now available,
and so potentially there is scope for another trial using
investigations such as magnetic resonance imaging or com-
puted tomography positron emission scanning. Such a study
is currently being planned by the Eastern Cooperative Group
in the USA but, outside such a study, there can be no
justification for performing investigations to detect metastatic
disease in asymptomatic patients during follow-up.
For what purpose do patients believe that
they are being followed up?
There is clearly some confusion among patients as to why
they are under follow-up. Although 68% of a group of women
were aware that follow-up was aimed at detecting recur-
rence, only 13% believed follow-up was to detect and treat
the side effects of treatment [8]. Thirty per cent thought that
follow-up might have some psychological benefit [8]. There is
little evidence that routine clinic visits are useful at detecting
either side effects of treatment or psychological problems.
Clinicians are not good at detecting psychological problems
[9], and women are not keen to discuss psychological
concerns in the clinic for various reasons, including
embarrassment, feeling rushed and not wanting to waste the
doctor’s time. Studies also show that up to 71% of patients
suffer distress during follow-up clinic visits, and reducing
clinic visits does not appear to reduce quality of life [10]. This
suggests that such visits do not contribute significantly to the
detection and amelioration of physical or psychosocial
problems.
Patterns of relapse
Although there is a peak of recurrence within the first 3 years,
much of this is accounted for by distant disease. Moreover,
recurrence continues beyond this time, and the annual rate of
local recurrence is constant for at least the first 10 years [11].
The study conducted by Saphner and coworkers [11]
showed that there are in fact more recurrences after the first
5 years than during the first 5 years after treatment, and so
recurrence is certainly not restricted to the first 5 years. A
higher early rate of relapse was observed in this study in
patients with multiple positive nodes, although after year 5
the rates of local relapse were similar for all women who were
node positive, regardless of the number of nodes involved.
Few studies have examined the pattern and timing of
potentially treatable relapses along with the method of
detection and the impact that the method of detection has on
outcome. Between 1991 and 1998, a total of 1,312 patients
were treated for early stage breast cancer by breast con-
serving surgery, axillary node sampling or clearance and
postoperative radiotherapy to the breast with/without ipsi-
lateral lymphatics in the Edinburgh Breast Unit [12]. Systemic
therapy was given according to local and national guidelines.
The mean age of this group of patients was 56 years, and
there were 354 node-positive patients and 958 node-
negative patients. A total of 110 patients were identified who
had treatable locoregional relapses: 48 in the ipsilateral axilla,
of whom only three were node positive; 25 in the ipsilateral
axilla; 35 in the controlateral breast; and two patients had
recurrence in both breasts simultaneously. The annual rate of
locoregional recurrence was constant at approximately 1.5%
over the first 10 years. The mode of detection of relapse is
summarized in Table 1. Overall, 51% of relapses were
detected mammographically, 33.5% were detected by the
patient, 13.5% were detected by the clinician, and 2% were
detected incidentally during surgery for reduction on the
opposite breast. The rate of clinical detections per annual
clinic visit was extremely low, at fewer than 2 per 1,000 visits,
whereas the mammographic detection rate was similar to that
seen within the screening programme, at 5.37 per 1,000
mammograms. Looking at patients subdivided by method of
detection, the overall survival in patients who recurred locally
was significantly reduced in the cohort of women whose
relapse was diagnosed clinically as compared with those
detected by the patient or by mammography (P = 0.0002;
log-rank test, two degrees of freedom). This difference in
outcome remains significant even if patients with axillary
disease are excluded (P = 0.0004).
It has been suggested that breast cancer follow-up can be
stratified on the basis of known prognostic factors, but
neither tumour size nor node status can accurately predict
local recurrence or contralateral disease. Even tumour grade
is a poor predictor of local recurrence. Any patient with
breast cancer, when compared with a woman of the same
age without cancer, has a relative risk of 3 to 4 for developingPage 3 of 4
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a new cancer in the treated breast, as well as an increased
risk for developing cancer in the contralateral breast. This risk
persists for at least two decades after a breast cancer
diagnosis.
What is optimal follow-up?
Psychological concerns are common during follow-up, and
evidence suggests that nurses detect more psychological
problems than clinicians. Side effects of drug treatment are
common concerns, but again these are often underestimated
and unrecognized by clinicians. One solution to detect such
problems is to provide patients with self-completed quality of
life questionnaires, which are reliable and effective in
identifying such problems. Continuing clinical input will be
needed for some patients, particularly those who request
revisional and reconstructive surgery, those with serious side
effects from treatment, and those with signs and symptoms
that suggest recurrence. Clinical input will also be needed in
those who are candidates for switching to an aromatase
inhibitor agent after 2 or 5 years. Agreed protocols to cope
with long-term complications of treatment, including bone
health, must be in place for all women. Psychological support
should be available to all patients and focused when patients’
needs are greatest - not only at diagnosis and during treat-
ment, but also after treatment ends. One model that meets
the aims of detecting local recurrence is annual clinical
examination for 1 to 2 years and annual surveillance by mam-
mography for 10 to 20 years or until age 80 years. Investi-
gation of symptoms and timely communication of test results
to patients and primary care is an essential component of
follow-up, not only to help reduce anxiety but also to ensure
that all those managing a patient are aware of the results of
investigations, so that they can provide appropriate support.
What is clear is that the frequency of clinic visits advocated
by ASCO is inappropriate, and these visits do not achieve
their aim. The status quo cannot continue. It is time for
ASCO, NICE and others involved in establishing guidelines
to utilize the large database of evidence that is currently
available and abandon extended clinical follow-up pro-
grammes for patients with breast cancer. They are an
ineffective use of time both for patients and for the doctors
who are involved in their care.
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Site of relapse and method of detection
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Bilateral breast 0 0 1 (1) 0 1 (1)
Total 13 (8) 15 (7) 56 (13) 24 (7) 108 (35)
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